Back to today’s briefing

Story perspectives

Roche Acquires Zealand's Obesity Drug for $5.3 Billion

3/13/2025

39 8

Summary

Story summary

Roche has made a bold move by acquiring Zealand Pharma's obesity drug, petrelintide, in a staggering deal valued at up to $5.3 billion. This strategic partnership positions Roche to challenge industry giants Novo Nordisk and Eli Lilly in the weight-loss arena. Following the news, Zealand's shares skyrocketed by 28%, while Roche enjoyed a 5.5% boost.

1 of 1

Story summary

Roche has made a bold move by acquiring Zealand Pharma's obesity drug, petrelintide, in a staggering deal valued at up to $5.3 billion. This strategic partnership positions Roche to challenge industry giants Novo Nordisk and Eli Lilly in the weight-loss arena. Following the news, Zealand's shares skyrocketed by 28%, while Roche enjoyed a 5.5% boost.